Oral Peptides: Why Most of Them Do Not Survive the Journey

A peptide is a short chain of amino acids. So is a piece of protein in your lunch. Your digestive system does not distinguish between them, and it is extremely good at breaking both into fragments.

That single fact explains why almost every compound discussed on this site is injected, and why oral versions are treated with scepticism.

What a swallowed peptide runs into

1. Stomach acid. A pH around 1.5 to 3.5 degrades many peptide structures before anything else happens.

2. Proteases. Pepsin in the stomach, then trypsin and chymotrypsin in the small intestine, exist specifically to cut peptide bonds.

3. The intestinal wall. Peptides are large and often charged, which makes crossing the epithelium difficult.

4. First-pass metabolism. Anything absorbed goes to the liver before reaching general circulation.

Each stage removes a share of the dose. The result for most peptides is oral bioavailability in the low single-digit percentages or less.

How oral formulations get around it

Making a peptide orally viable is a formulation problem, and it is solvable at cost:

• Absorption enhancers. Oral semaglutide uses a co-formulated agent that transiently aids absorption in the stomach.

• Enteric coatings. Protect through the stomach and release further down.

• Protease inhibitors. Co-formulated to slow enzymatic breakdown.

• Structural modification. Altering the peptide itself to resist enzymes.

• Much larger doses. Compensating for losses by starting with far more.

Oral semaglutide is the clearest worked example — an approved oral formulation of a peptide, achieved through formulation engineering rather than by the peptide being naturally absorbable.

Where oral genuinely makes sense

For compounds acting locally in the gut, poor absorption is the point rather than the problem.

• Larazotide acts on intestinal tight junctions from the luminal side. Systemic absorption would defeat it.

• KPV appears in gut-focused research where local delivery to intestinal tissue is the objective.

• BPC-157 is described as stable in gastric juice, which is the basis for oral products — though stability is not the same as absorption. See the BPC-157 guide.

Compounds that are not peptides

Some things sold as "oral peptides" are not peptides at all, and their oral activity is unremarkable because small molecules are routinely orally available.

5-Amino-1MQ and tesofensine are both small molecules. Their being oral tells you nothing about peptide delivery, because they were never facing the peptide problem.

Frequently asked questions

Do oral BPC-157 capsules work?

The compound is described as gastric-juice stable, which supports the idea. Absorption and the dose required orally are not established, and no figure transfers from injection studies.

Why is oral semaglutide a lower dose than expected?

It is a higher one. Oral formulations use substantially more drug than injectable equivalents precisely because so little is absorbed.

Are nasal sprays better than oral?

Nasal delivery avoids digestion and can absorb better for some compounds, but is more variable — depending on technique, mucosal condition, and formulation.